Over 266 million patients around the world are struggling with debilitating back pain, trying to avoid
invasive surgeries and the potential of opioid addiction. Spine BioPharma has developed a portfolio of
non-surgical solutions that will reduce pain, restore function and slow or stop pathological spinal disease
progression without using opioids. Spine BioPharma’s lead candidate, Remedisc™ is a first-in-class
disease-modifying therapeutic for the treatment of degenerative disc disease, offering clinical benefits of
pain relief, restoration of function and potential prevention of disease progression.